Zynerba Pharmaceuticals, Inc. engages in the provision of pharmaceutically-produced transdermal cannabinoid therapies. It focuses on research and development of rare and near-rare neuropsychiatric conditions. It offers Zygel product which formulated as a permeation-enhanced gel for transdermal delivery. The company was founded by Audra L. Stinchcomb on January 31, 2007 and is headquartered in Devon, PA. The listed name for ZYNE is Zynerba Pharmaceuticals, Inc. Common Stock.

0 views0 comments

Recent Posts

See All

Domain Name Launch Day

Today indicainvestorsclub.com went live. Looking forward to where this might go.